2-Hydroxy-5-carbomethoxybenzyloxyamine

A new potent inhibitor of histidine decarboxylase

Z. Huszti, E. Kasztreiner, M. Kürti, M. Fekete, J. Borsy

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Histidine decarboxylase inhibiting and histamine lowering effects of 2-hydroxy-5-carbomethoxybenzyloxyamine have been studied in detail. The compound proved to be a potent inhibitor of both rat stomach pyloric histidine decarboxylase and guinea-pig liver aromatic l-amino acid decarboxylase, showing a more pronounced effect on the former enzyme. The type of inhibitions were ascribed as reversible and competitive with respect to substrate and coenzyme in both cases. The Ki values for histidine and pyridoxal phosphate were 1 × 10-7 and 2.5 × 10-7M; for5-hydroxytryptamine and pyridoxal phosphate, 1 × 10-6 and 5 × 10-6 M. Studies with the pyridoxal phosphate oxim of this substance showed no remarkable inhibition of the nonspecific enzyme, and substantially less effect on specific decarboxylase than that obtained with 2-hydroxy-5-carbomethoxybenzyloxyamine itself. These results suggested that the inhibiting effect of the compound is partly directly on the coenzyme, forming a pyridoxal phosphate inactivator complex, but mainly on the apoenzyme, displacing pyridoxal phosphate from the apoenzyme. The fact that the inhibitory activity of the compound mainly depended on the relative strength of binding of pyridoxal phosphate to apoenzyme, showing substantially less effect on aromatic l-amino acid decarboxylase and on diamine oxidase than that on histidine decarboxylase, confirmed this assumption. Administration of the inhibitor to male rats resulted in lower levels of histamine in stomach, lungs, heart and skin. The minimum effective dose of the compound was 15 mg/kg maximal effects were obtained with doses of 45 mg/kg in lungs, heart and skin and 135 mg/kg in stomach. The maximal effects were observed 1-2 hr after the treatment and were significantly less at 5 hr. Repeated administration resulted in lower histamine levels than after single treatments. No toxic effects were apparent during repeated and prolonged administrations of the inhibitor.

Original languageEnglish
Pages (from-to)2253-2265
Number of pages13
JournalBiochemical Pharmacology
Volume22
Issue number18
DOIs
Publication statusPublished - Sep 15 1973

Fingerprint

Histidine Decarboxylase
Pyridoxal Phosphate
Apoenzymes
Carboxy-Lyases
Aromatic-L-Amino-Acid Decarboxylases
Stomach
Coenzymes
Carboxylic acids
Histamine
Rats
Skin
Histamine Agents
Amine Oxidase (Copper-Containing)
Amino Acids
Lung
Poisons
Enzymes
Histidine
Liver
2-hydroxy-5-carbomethoxybenzyloxyamine

ASJC Scopus subject areas

  • Pharmacology

Cite this

2-Hydroxy-5-carbomethoxybenzyloxyamine : A new potent inhibitor of histidine decarboxylase. / Huszti, Z.; Kasztreiner, E.; Kürti, M.; Fekete, M.; Borsy, J.

In: Biochemical Pharmacology, Vol. 22, No. 18, 15.09.1973, p. 2253-2265.

Research output: Contribution to journalArticle

Huszti, Z. ; Kasztreiner, E. ; Kürti, M. ; Fekete, M. ; Borsy, J. / 2-Hydroxy-5-carbomethoxybenzyloxyamine : A new potent inhibitor of histidine decarboxylase. In: Biochemical Pharmacology. 1973 ; Vol. 22, No. 18. pp. 2253-2265.
@article{d7d460d5eec04e5da008fe1c9da21597,
title = "2-Hydroxy-5-carbomethoxybenzyloxyamine: A new potent inhibitor of histidine decarboxylase",
abstract = "Histidine decarboxylase inhibiting and histamine lowering effects of 2-hydroxy-5-carbomethoxybenzyloxyamine have been studied in detail. The compound proved to be a potent inhibitor of both rat stomach pyloric histidine decarboxylase and guinea-pig liver aromatic l-amino acid decarboxylase, showing a more pronounced effect on the former enzyme. The type of inhibitions were ascribed as reversible and competitive with respect to substrate and coenzyme in both cases. The Ki values for histidine and pyridoxal phosphate were 1 × 10-7 and 2.5 × 10-7M; for5-hydroxytryptamine and pyridoxal phosphate, 1 × 10-6 and 5 × 10-6 M. Studies with the pyridoxal phosphate oxim of this substance showed no remarkable inhibition of the nonspecific enzyme, and substantially less effect on specific decarboxylase than that obtained with 2-hydroxy-5-carbomethoxybenzyloxyamine itself. These results suggested that the inhibiting effect of the compound is partly directly on the coenzyme, forming a pyridoxal phosphate inactivator complex, but mainly on the apoenzyme, displacing pyridoxal phosphate from the apoenzyme. The fact that the inhibitory activity of the compound mainly depended on the relative strength of binding of pyridoxal phosphate to apoenzyme, showing substantially less effect on aromatic l-amino acid decarboxylase and on diamine oxidase than that on histidine decarboxylase, confirmed this assumption. Administration of the inhibitor to male rats resulted in lower levels of histamine in stomach, lungs, heart and skin. The minimum effective dose of the compound was 15 mg/kg maximal effects were obtained with doses of 45 mg/kg in lungs, heart and skin and 135 mg/kg in stomach. The maximal effects were observed 1-2 hr after the treatment and were significantly less at 5 hr. Repeated administration resulted in lower histamine levels than after single treatments. No toxic effects were apparent during repeated and prolonged administrations of the inhibitor.",
author = "Z. Huszti and E. Kasztreiner and M. K{\"u}rti and M. Fekete and J. Borsy",
year = "1973",
month = "9",
day = "15",
doi = "10.1016/0006-2952(73)90006-3",
language = "English",
volume = "22",
pages = "2253--2265",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "18",

}

TY - JOUR

T1 - 2-Hydroxy-5-carbomethoxybenzyloxyamine

T2 - A new potent inhibitor of histidine decarboxylase

AU - Huszti, Z.

AU - Kasztreiner, E.

AU - Kürti, M.

AU - Fekete, M.

AU - Borsy, J.

PY - 1973/9/15

Y1 - 1973/9/15

N2 - Histidine decarboxylase inhibiting and histamine lowering effects of 2-hydroxy-5-carbomethoxybenzyloxyamine have been studied in detail. The compound proved to be a potent inhibitor of both rat stomach pyloric histidine decarboxylase and guinea-pig liver aromatic l-amino acid decarboxylase, showing a more pronounced effect on the former enzyme. The type of inhibitions were ascribed as reversible and competitive with respect to substrate and coenzyme in both cases. The Ki values for histidine and pyridoxal phosphate were 1 × 10-7 and 2.5 × 10-7M; for5-hydroxytryptamine and pyridoxal phosphate, 1 × 10-6 and 5 × 10-6 M. Studies with the pyridoxal phosphate oxim of this substance showed no remarkable inhibition of the nonspecific enzyme, and substantially less effect on specific decarboxylase than that obtained with 2-hydroxy-5-carbomethoxybenzyloxyamine itself. These results suggested that the inhibiting effect of the compound is partly directly on the coenzyme, forming a pyridoxal phosphate inactivator complex, but mainly on the apoenzyme, displacing pyridoxal phosphate from the apoenzyme. The fact that the inhibitory activity of the compound mainly depended on the relative strength of binding of pyridoxal phosphate to apoenzyme, showing substantially less effect on aromatic l-amino acid decarboxylase and on diamine oxidase than that on histidine decarboxylase, confirmed this assumption. Administration of the inhibitor to male rats resulted in lower levels of histamine in stomach, lungs, heart and skin. The minimum effective dose of the compound was 15 mg/kg maximal effects were obtained with doses of 45 mg/kg in lungs, heart and skin and 135 mg/kg in stomach. The maximal effects were observed 1-2 hr after the treatment and were significantly less at 5 hr. Repeated administration resulted in lower histamine levels than after single treatments. No toxic effects were apparent during repeated and prolonged administrations of the inhibitor.

AB - Histidine decarboxylase inhibiting and histamine lowering effects of 2-hydroxy-5-carbomethoxybenzyloxyamine have been studied in detail. The compound proved to be a potent inhibitor of both rat stomach pyloric histidine decarboxylase and guinea-pig liver aromatic l-amino acid decarboxylase, showing a more pronounced effect on the former enzyme. The type of inhibitions were ascribed as reversible and competitive with respect to substrate and coenzyme in both cases. The Ki values for histidine and pyridoxal phosphate were 1 × 10-7 and 2.5 × 10-7M; for5-hydroxytryptamine and pyridoxal phosphate, 1 × 10-6 and 5 × 10-6 M. Studies with the pyridoxal phosphate oxim of this substance showed no remarkable inhibition of the nonspecific enzyme, and substantially less effect on specific decarboxylase than that obtained with 2-hydroxy-5-carbomethoxybenzyloxyamine itself. These results suggested that the inhibiting effect of the compound is partly directly on the coenzyme, forming a pyridoxal phosphate inactivator complex, but mainly on the apoenzyme, displacing pyridoxal phosphate from the apoenzyme. The fact that the inhibitory activity of the compound mainly depended on the relative strength of binding of pyridoxal phosphate to apoenzyme, showing substantially less effect on aromatic l-amino acid decarboxylase and on diamine oxidase than that on histidine decarboxylase, confirmed this assumption. Administration of the inhibitor to male rats resulted in lower levels of histamine in stomach, lungs, heart and skin. The minimum effective dose of the compound was 15 mg/kg maximal effects were obtained with doses of 45 mg/kg in lungs, heart and skin and 135 mg/kg in stomach. The maximal effects were observed 1-2 hr after the treatment and were significantly less at 5 hr. Repeated administration resulted in lower histamine levels than after single treatments. No toxic effects were apparent during repeated and prolonged administrations of the inhibitor.

UR - http://www.scopus.com/inward/record.url?scp=0015862284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015862284&partnerID=8YFLogxK

U2 - 10.1016/0006-2952(73)90006-3

DO - 10.1016/0006-2952(73)90006-3

M3 - Article

VL - 22

SP - 2253

EP - 2265

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 18

ER -